玻璃体内注射曲安奈德植入物（ILUVIEN®）治疗糖尿病性黄斑水肿：文献综述
Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review.
作者信息
Massa Horace, Nagar Anindyt M, Vergados Athanasios, Dadoukis Panagiotis, Patra Sudeshna, Panos Georgios D
机构信息
1 Department of Ophthalmology, Geneva University Hospitals, Geneva, Switzerland.
*These authors contributed equally to this work.
出版信息
J Int Med Res. 2019 Jan;47(1):31-43. doi: 10.1177/0300060518816884. Epub 2018 Dec 16.
Abstract
Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy and may lead to severe visual loss. In this review, we describe the pathophysiology of DMO and review current therapeutic options such as macular laser photocoagulation, anti-vascular endothelial growth factor agents, and steroid implants with a focus on the new fluocinolone acetonide implant, ILUVIEN®. The results of the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) studies are also presented together with the results of real-world studies to support the clinical use of ILUVIEN® in achieving efficient resolution of DMO and improving vision and macular anatomy in this challenging group of patients.
摘要
糖尿病性黄斑水肿（DMO）是糖尿病视网膜病变的常见并发症，可能导致严重视力丧失。在本综述中，我们描述了DMO的病理生理学，并回顾了当前的治疗选择，如黄斑激光光凝、抗血管内皮生长因子药物和类固醇植入物，重点介绍新型氟轻松丙酮化物植入物ILUVIEN®。还介绍了氟轻松丙酮化物治疗糖尿病性黄斑水肿（FAME）研究的结果以及真实世界研究的结果，以支持ILUVIEN®在这一具有挑战性的患者群体中实现DMO有效消退、改善视力和黄斑解剖结构的临床应用。
相似文献
1
Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review.
J Int Med Res. 2019 Jan;47(1):31-43. doi: 10.1177/0300060518816884. Epub 2018 Dec 16.
2
[Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema].
J Fr Ophtalmol. 2015 Feb;38(2):159-67. doi: 10.1016/j.jfo.2014.09.007. Epub 2015 Jan 16.
3
Intravitreal Fluocinolone Acetonide Implant (ILUVIEN) for the Treatment of Retinal Conditions. A Review of Clinical Studies.
Drug Des Devel Ther. 2023 Mar 30;17:961-975. doi: 10.2147/DDDT.S403259. eCollection 2023.
4
Fluocinolone acetonide intravitreal implant (Iluvien®): in diabetic macular oedema.
Drugs. 2013 Feb;73(2):187-93. doi: 10.1007/s40265-013-0010-x.
5
Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years.
BMC Ophthalmol. 2018 Feb 27;18(1):62. doi: 10.1186/s12886-018-0726-1.
6
The long-term efficacy and safety of fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN) in diabetic macular oedema in a multi-ethnic inner-city population.
Eur J Ophthalmol. 2021 Mar;31(2):620-629. doi: 10.1177/1120672119898414. Epub 2020 Jan 6.
7
ILUVIEN technology in the treatment of center-involving diabetic macular edema: a review of the literature.
Ther Deliv. 2018 Aug;9(8):547-556. doi: 10.4155/tde-2018-0006. Epub 2018 Jun 26.
8
Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies.
BMC Health Serv Res. 2019 Jan 9;19(1):22. doi: 10.1186/s12913-018-3804-4.
9
Treatment of chronic diabetic macular oedema with intravitreal fluocinolone acetonide implant; real-life analysis of outcomes during overall treatment period.
Eur J Ophthalmol. 2022 Nov;32(6):3629-3636. doi: 10.1177/11206721221097587. Epub 2022 Apr 28.
10
Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN): A Review in Diabetic Macular Edema.
Drugs. 2017 Apr;77(5):575-583. doi: 10.1007/s40265-017-0722-4.
引用本文的文献
1
Persistent Diabetic Macular Edema: A Comprehensive Review of Current Treatments and Emerging Therapeutic Options.
J Curr Ophthalmol. 2025 Jun 5;36(3):229-241. doi: 10.4103/joco.joco_133_24. eCollection 2024 Jul-Sep.
2
Suprachoroidal implantation of corticosteroid slow release implants for the treatment of cystoid macular edema.
Sci Rep. 2025 Jun 20;15(1):20166. doi: 10.1038/s41598-025-05611-y.
3
Overview of processed excipients in ocular drug delivery: Opportunities so far and bottlenecks.
Heliyon. 2023 Dec 23;10(1):e23810. doi: 10.1016/j.heliyon.2023.e23810. eCollection 2024 Jan 15.
4
Suprachoroidal Injection: A Novel Approach for Targeted Drug Delivery.
Pharmaceuticals (Basel). 2023 Sep 1;16(9):1241. doi: 10.3390/ph16091241.
5
Incidence and treatment approach of intraocular pressure elevation after various types of local steroids for retinal diseases.
Graefes Arch Clin Exp Ophthalmol. 2023 Dec;261(12):3569-3579. doi: 10.1007/s00417-023-06163-5. Epub 2023 Jul 11.
6
Intravitreal Fluocinolone Acetonide Implant (ILUVIEN) for the Treatment of Retinal Conditions. A Review of Clinical Studies.
Drug Des Devel Ther. 2023 Mar 30;17:961-975. doi: 10.2147/DDDT.S403259. eCollection 2023.
7
Diabetic Macular Oedema Guidelines: An Australian Perspective.
J Ophthalmol. 2023 Feb 14;2023:6329819. doi: 10.1155/2023/6329819. eCollection 2023.
8
Suprachoroidal injection of triamcinolone acetonide plus intravitreal bevacizumab in diabetic macular edema: a randomized pilot trial.
BMC Ophthalmol. 2023 Jan 27;23(1):40. doi: 10.1186/s12886-023-02790-y.
9
Current Treatments and Innovations in Diabetic Retinopathy and Diabetic Macular Edema.
Pharmaceutics. 2022 Dec 29;15(1):122. doi: 10.3390/pharmaceutics15010122.
10
Biomarkers to Predict the Success of Treatment with the Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Uveitic Macular Edema.
Pharmaceutics. 2022 Mar 22;14(4):688. doi: 10.3390/pharmaceutics14040688.
本文引用的文献
1
Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries.
Br J Ophthalmol. 2019 Aug;103(8):1072-1077. doi: 10.1136/bjophthalmol-2018-312284. Epub 2018 Sep 21.
2
Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years.
BMC Ophthalmol. 2018 Feb 27;18(1):62. doi: 10.1186/s12886-018-0726-1.
3
[Cost Comparison of Licensed Intravitreal Therapies for Insufficiently Anti-VEGF Responding Fovea Involving Diabetic Macular Edema in Germany].
Klin Monbl Augenheilkd. 2019 Feb;236(2):180-191. doi: 10.1055/s-0043-125076. Epub 2018 Feb 16.
4
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
JAMA Ophthalmol. 2018 Mar 1;136(3):257-269. doi: 10.1001/jamaophthalmol.2017.6565.
5
Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
Ophthalmic Res. 2018;59(2):68-75. doi: 10.1159/000484091. Epub 2017 Dec 16.
6
Recent advances in the management and understanding of diabetic retinopathy.
F1000Res. 2017 Nov 29;6:2063. doi: 10.12688/f1000research.12662.1. eCollection 2017.
7
DISLODGEMENT OF FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT INTO THE INFUSION CANNULA DURING VITRECTOMY FOR RETINAL DETACHMENT.
Retin Cases Brief Rep. 2020 Summer;14(3):215-217. doi: 10.1097/ICB.0000000000000678.
8
Real-World Cost Savings Demonstrated by Switching Patients with Refractory Diabetic Macular Edema to Intravitreal Fluocinolone Acetonide (Iluvien): A Retrospective Cost Analysis Study.
Ophthalmol Ther. 2018 Jun;7(1):75-82. doi: 10.1007/s40123-017-0114-6. Epub 2017 Nov 10.
9
New Drugs and New Posterior Delivery Methods in CME.
Curr Ophthalmol Rep. 2017 Jun;5(2):160-168. doi: 10.1007/s40135-017-0134-3. Epub 2017 Apr 7.
10
Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema.
Curr Med Res Opin. 2017 Oct;33(sup2):33-43. doi: 10.1080/03007995.2017.1366662. Epub 2017 Sep 7.
Zotero 插件